https://www.selleckchem.com/products/c-178.html
No notable subjective or objective adverse effects were observed in this cohort. By extrapolating the observed single-dose D /D receptor occupancy data in healthy participants, multiple doses of brexpiprazole 2mg/day and above are expected to result in an efficacious brexpiprazole concentration, consistent with clinically active doses in schizophrenia and major depressive disorder. ClinicalTrials.gov NCT00805454 December 9, 2008. ClinicalTrials.gov NCT00805454 December 9, 2008.As a chronic neurodegenerative disease, Parkinson's disease re